About: REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Sector: Healthcare
Industry: Biotechnology
Latest price: $7.60 (+1.95%)
RGNX NASDAQ Regenxbio Inc
Regenxbio Inc share price
RGNX price activity
Último preço
$ 7,600
Variação (24h)
0,15 USD (1,95%)
Volume
1M
Volume (média 4 sem.)
-
Abertura
$ 7,31
Variação do dia
$ 7,20 - $ 7,73
Fechamento anterior
$ 7,45
Último negócio
07 Oct, 8:11 pm GMT+0
Atrasado
07 Oct, 8:11 pm GMT+0
RGNX price performance
Atrasado
07 Oct, 8:11 pm GMT+0
quote.marketSignals